In an interview to CNBC-TV18, D Ram Reddy, JMD of Balaji Amines said that we are seeing support for dimethylacetamide post anti-dumping duty imposition.
Balaji Amines posted a strong set of earnings in Q3. There has been a 22 percent revenue growth led by the amines division and margins have also improved this quarter. In an interview with CNBC-TV18, D Ram Reddy, Joint MD at Balaji Amines discussed the results and his outlook for the company.
Balaji Amines in focus after company receives an allotment of 3.6 lakh square metre of land in Solapur, the land will be used for project expansion. In an interview to CNBC-TV18, D Ram Reddy, Joint MD of the company spoke at length about the same.
D Ram Reddy, JMD, Balaji Amines said the hotel business is expected to improve going forward.
Balaji Amines receives approval from the Ministry of Environment, Forest and Climate Change for its expansion project. In an interview to CNBC-TV18, D Ram Reddy, Joint MD of Balaji Amines discussed this further.
In an interview with CNBC-TV18, D Ram Reddy, Joint MD of Balaji Amines said that the company will sustain 20 percent margins in FY17 and has capex plans worth Rs 30-40 crore to set up a Morpholine unit with an installed capacity of 10000 million tonne per annum (MTPA).
High capacity utilisation led to a 70 percent growth for Balaji Amines in FY16, Ram Reddy, the joint MD of the company said. He expects 50 percent growth to be sustainable in FY17.
Low oil prices have led to a 30 percent volume growth, D Ram Reddy, JMD of the company said. Reddy expects volume growth of 30-35 percent in FY17.
Balaji Amines saw a dip in profits in the fourth quarter results posted recently. The profits are down by an odd 56% at Rs 1.67 crore versus Rs 3.84 crore. There is huge interest cost and tax burdens that have impacted their profitability, says D Ram Reddy, director-commercial of Balaji Amines.
In an interview with CNBC-TV18, D Ram Reddy, Balaji Amines, spoke about the latest happenings in his company and sector.
In an interview with CNBC-TV18’s Reema Tendulkar and Ekta Batra, Pratap Reddy, MD, Balaji Amines spoke about the results and his outlook for the company.